OCT 21, 2021 8:00 AM PDT

Generating protein reagents to evaluate the antibody and CD8+ T cell responses to SARS-CoV-2

Speaker

Abstract

DATE: October 21, 2021

TIME:  8:00am PDT

 

Coronavirus disease 2019 (COVID-19) is a global health crisis caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and there is a critical need to produce large quantities of high-quality SARS-CoV-2 antigens for characterization and evaluation of antibody responses to SARS-CoV-2. To address this, we optimized expression and purification of two previously reported SARS-CoV-2 Spike (S) protein constructs and show that ExpiCHO-S™ cells produce enhanced yields of both S proteins compared to other expression systems. Our expression and purification strategy yielded high quality material to allow biochemical, biophysical, and structural (cryo-EM) characterization of the SARS-CoV-2 S protein. We also generated protein microarrays using S protein along with other SARS-CoV-2 antigens (i.e., nucleocapsid) to detect SARS-CoV-2 antibodies in COVID-19 convalescent individuals. Our current efforts are focused on evaluating and activating CD8+ T cells that are specific for SARS-CoV-2. To this end we have developed protein biologics that behave similarly to antigen presenting cells and allow us to activate T cells in an antigen specific (i.e., peptide from an antigen is linked to an MHC molecule) manner. These peptide:MHC molecules are then linked to co-stimulatory molecules to generate proteins we refer to as synTac (artificial immunological synapse for T cell activation). We will develop SARS-CoV-2 synTac protein biologics to activate SARS-CoV-2 CD8+ T cells to determine if this will provide long-term immunity against SARS-CoV-2.

 

Learning objectives:

  • Discuss and lean about glycosylated proteins and discuss different expression platforms for glycoproteins. This can be applied to the SARS-CoV-2 S protein and how glycosylated (or hyperglycosylated) S protein can be utilized for downstream clinical and basic science applications.
  • Describe how SARS-CoV-2 antigens have been used to study antibody responses to COVID-19.
  • Demonstrate how synTac protein biologics activate T cells in an antigen specific manner and compare synTac proteins with current immunotherapies.

 

Webinars will be available for unlimited on-demand viewing after live event.

 


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
MAY 19, 2022 8:00 AM PDT
MAY 19, 2022 8:00 AM PDT
Date: May 19, 2022 Time: 8:00am (PDT), 11:00pm (EDT), 5:00pm (CEST) Mass spectrometry (MS)-based proteomic technologies are increasingly applied in a clinical context for disease classific...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
JUN 29, 2022 8:00 AM PDT
JUN 29, 2022 8:00 AM PDT
Date: June 29, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CEST) As of May 2022, there have been more than 500 million confirmed cases of COVID-19, including numerous variants. Additiona...
MAR 23, 2022 11:00 AM PDT
MAR 23, 2022 11:00 AM PDT
Date: March 23, 2021 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEDT) In this presentation, Dr. Middleton will review the development and deployment of large-scale saliva-based COVID-19 test...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
Loading Comments...
Show Resources